Cargando…
Obesity reduces the anticancer effect of AdipoRon against orthotopic pancreatic cancer in diet-induced obese mice
The antidiabetic adiponectin receptor agonist AdipoRon has been shown to suppress the tumour growth of human pancreatic cancer cells. Because obesity and diabetes affect pancreatic cancer progression and chemoresistance, we investigated the effect of AdipoRon on orthotopic tumour growth of Panc02 pa...
Autores principales: | Takenaga, Keizo, Akimoto, Miho, Koshikawa, Nobuko, Nagase, Hiroki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7859201/ https://www.ncbi.nlm.nih.gov/pubmed/33536560 http://dx.doi.org/10.1038/s41598-021-82617-2 |
Ejemplares similares
-
Antidiabetic adiponectin receptor agonist AdipoRon suppresses tumour growth of pancreatic cancer by inducing RIPK1/ERK-dependent necroptosis
por: Akimoto, Miho, et al.
Publicado: (2018) -
AdipoRon accelerates bone repair of calvarial defect in diet-induced obesity mice
por: Wu, Xingwen, et al.
Publicado: (2023) -
Cancer cell-derived interleukin-33 decoy receptor sST2 enhances orthotopic tumor growth in a murine pancreatic cancer model
por: Takenaga, Keizo, et al.
Publicado: (2020) -
AdipoRon may be benefit for atherosclerosis prevention
por: Esfahani, Maryam, et al.
Publicado: (2017) -
AdipoRon, a new therapeutic prospect for Duchenne muscular dystrophy
por: Abou‐Samra, Michel, et al.
Publicado: (2020)